Prospective Evaluation of Malignancy in 17,708 Patients Randomized to Ezetimibe Versus Placebo
Analysis From IMPROVE-IT
Robert P. Giugliano, Baris Gencer, Stephen D. Wiviott, Jeong-Gun Park, Charles S. Fuchs, Wolfram Goessling, Thomas A. Musliner, Andrew M. Tershakovec, Michael A. Blazing, Robert Califf, Christopher P. Cannon and Eugene Braunwald
Cumulative Incidence Rates for the Primary Malignancy Endpoint by Treatment Arm
Simvastatin/ezetimibe (red) and placebo/ezetimibe (blue). The primary malignancy endpoint was defined as new, relapsing, or progressive malignancy (excluding nonmelanotic skin malignancy). The cumulative incidence plots were presented graphically using Kaplan-Meier product-limit method. CI = confidence interval; HR = hazard ratio.